# US 8,278,349 B2 · Cancer treatment using FTS and 2-deoxyglucose

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,349 B2
- Document ID: US8278349B2
- Status: Granted
- Kind: B2
- Application number: 12/085,628
- Filed: 2006-11-06
- Published: 2009-11-19
- Granted: 2012-10-02
- Earliest claimed: 2005-11-28
- Assignees: Ramot at Tel-Aviv University Ltd.
- Inventors: Yoel Kloog; Liat Goldberg; Michael Brownstein
- Web page: https://patentgrep.com/patent/US8278349B2

## CPC

- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/7004: Monosaccharides having only carbon, hydrogen and oxygen atoms
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of treating cancer by administering effective amounts of a Ras antagonist comprising FTS, or analogs thereof, or a pharmaceutically acceptable salt, and 2-deoxyglucose (2DG) to a patient are disclosed. Pharmaceutical compositions useful in treating cancer containing a Ras antagonist comprising FTS, or analogs thereof, or a pharmaceutically acceptable salt, and 2DG are also disclosed.

## Claims

### Claim 1

A pharmaceutical composition useful in the treatment of pancreatic cancer or a glioblastoma, comprising effective amounts of a Ras antagonist represented by the formula:
wherein
R1 represents farnesyl or geranylgeranyl;
R2 is COOR7, or CONR7R8, wherein R7 and R8 are each independently hydrogen, alkyl or alkenyl;
R3, R4, R5 and R6 are each independently hydrogen, alkyl, alkenyl, alkoxy, halo, trifluoromethyl, trifluoromethoxy, or alkylmercapto; and
X represents S; or a pharmaceutically acceptable salt thereof; and
2-deoxyglucose (2DG); and
a pharmaceutically acceptable carrier.

### Claim 2 (depends on 1)

The composition of claim 1, wherein said Ras antagonist is farnesylthiosalicylic acid (FTS).

### Claim 3 (depends on 1)

The composition of claim 1, wherein said Ras antagonist is S-geranylgeranyl-thiosalicylic acid (GGTS).

### Claim 4 (depends on 1)

The composition of claim 1, wherein said Ras antagonist is present in an amount of about 100 mg to about 500 mg.

### Claim 5 (depends on 1)

The composition of claim 1, wherein said 2DG is present in an amount of about 400 mg to about 1000 mg.

### Claim 6 (depends on 1)

The composition of claim 1, which is in the form of a tablet.

### Claim 7 (depends on 1)

The composition of claim 1, which is in the form of a capsule.

### Claim 8

A method of treating pancreatic cancer or a glioblastoma, comprising administering to a human in need thereof effective amounts of a Ras antagonist represented by the formula:
wherein
R1 represents farnesyl or geranylgeranyl;
R2 is COOR7, or CONR7R8, wherein R7 and R8 are each independently hydrogen, alkyl or alkenyl;
R3, R4, R5 and R6 are each independently hydrogen, alkyl, alkenyl, alkoxy, halo, trifluoromethyl, trifluoromethoxy, or alkylmercapto; and
X represents S; or a pharmaceutically acceptable salt thereof; and
2-deoxyglucose (2DG).

### Claim 9 (depends on 8)

The method of claim 8, wherein the Ras antagonist is FTS.

### Claim 10 (depends on 8)

The method of claim 8, wherein the Ras antagonist is GGTS.

### Claim 11 (depends on 8)

The method of claim 8, wherein the effective amount of the Ras antagonist is about 50 mg to about 1000 mg.

### Claim 12 (depends on 8)

The method of claim 8, wherein the effective amount of the 2DG is about 500 mg to about 6000 mg.

### Claim 13 (depends on 8)

The method of claim 8, wherein the treatment comprises separate administration of the Ras antagonist and the 2DG.

### Claim 14 (depends on 8)

The method of claim 8, wherein the treatment comprises oral administration of the Ras antagonist and 2DG in the same oral dosage form.

### Claim 15 (depends on 8)

The method of claim 8, wherein the treatment comprises oral administration of the Ras antagonist and parenteral administration of 2DG.

### Claim 16 (depends on 8)

The method of claim 8, wherein the treatment comprises convection-enhanced delivery of the Ras antagonist and 2DG.

### Claim 17 (depends on 8)

The method of claim 8, wherein the cancer is pancreatic cancer.

### Claim 18 (depends on 8)

The method of claim 8, wherein the cancer is a glioblastoma.
